華納藥廠(688799.SH):膠體果膠鉍膠囊、枸櫞酸鉍鉀膠囊、枸櫞酸鉍鉀顆粒等鉍劑產品已列入2023年國家醫保目錄和2018年國家基本藥物目錄
格隆匯12月20日丨華納藥廠(688799.SH)近期接受特定對象調研時表示,公司鉍劑系列產品包括膠體果膠鉍幹混懸劑、膠體果膠鉍膠囊、枸櫞酸鉍鉀膠囊、枸櫞酸鉍鉀顆粒、膠體酒石酸鉍膠囊等。其中,膠體果膠鉍、膠體酒石酸鉍產品原料製劑配套完善,枸櫞酸鉍鉀膠囊是首家通過一致性評價的產品。膠體果膠鉍膠囊、枸櫞酸鉍鉀膠囊、枸櫞酸鉍鉀顆粒等鉍劑產品已列入2023年國家醫保目錄和2018年國家基本藥物目錄。
根據米內網2022年數據,公司膠體果膠鉍製劑在國內城市公立醫院、城市社區醫院、縣級公立醫院、鄉鎮衞生院市場佔有率排名第一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.